Source: Annual Congress 2008 - Management, quality aspects and prognosis in thoracic oncology
Disease area: Thoracic oncology



Rating:

Share or cite this content

Citations should be made in the following way:
Y. E. Ong, S. Goddard, A. Draper (Tooting, London, United Kingdom). Comparison of non-small cell lung cancer (NSCLC) management and survival in 1995 and 2005 at a London teaching hospital. Eur Respir J 2008; 32: Suppl. 52, 1402

Member's Comments

No comment yet.

Related content which might interest you: Current surgical treatment of nonsmall cell lung cancer 2001 Source: Eur Respir J 2002; 19: 61S-70S Year: 2002 Trends in drug costs and overall survival in patients diagnosed with metastatic non-small cell lung cancer (NSCLC) Source: International Congress 2019 – How to guide patients to reach a balance between costs and personal needs: quality indicators of effectiveness Year: 2019 Use of erlotinib in management of advanced non-small cell lung cancer (NSCLC): The Czech Republic experience with the treatment of a non-selected population of 1735 patients (pts) Source: Annual Congress 2011 - Treatment of lung cancer Year: 2011 Time trends in treatment and survival of non-small cell lung cancer in The Netherlands Source: Annual Congress 2010 - Quality management for lung cancer patients Year: 2010 Clinical outcome of Pembrolizumab (PEMB) monotherapy in patients (pts) with advanced non-small cell lung cancer (NSCLC) – Reports from routine clinical care. Source: International Congress 2019 – Treatment of lung cancer Year: 2019 Trends of the proportion of small-cell lung cancer (SCLC) over the last 20 year: a university medical center experience Source: Annual Congress 2007 - Rare tumours, risk factors and epidemiology in thoracic oncology Year: 2007 Surveillance imaging and recurrence rates following surgery for non-small cell lung cancer (NSCLC). Source: Virtual Congress 2020 – Localised non-small cell lung cancer Year: 2020 Survival with in-operable non-small cell lung cancer in U.K district general hospital: Is chemotherapy better than active supportive care? Source: Annual Congress 2010 - Best supportive care and palliation for lung cancer patients Year: 2010 Osimertinib as a second-line treatment for EGFR-mutated non-small cell lung cancer: the experience of a Pulmonology department Source: Virtual Congress 2020 – Real-world data and registries of thoracic oncology Year: 2020 Advanced non-small cell lung cancer (NSCLC): observation of chemotherapy in 5 European countries Source: Annual Congress 2007 - Therapy of lung cancer Year: 2007 Treatment of  non-small cell lung cancer (NSCLC) - the state of the art and beyond Source: International Congress 2017 – State of the art session: "Lung cancer" Year: 2017 The role of palliative radiotherapy in locally advanced non small cell lung cancer Source: Annual Congress 2007 - Therapy of lung cancer Year: 2007 Results of surgical treatment in elderly patients with non-small cell lung cancer (NSCLC) Source: Eur Respir J 2002; 20: Suppl. 38, 463s Year: 2002 Quality indicators in lung cancer care-review of resection rates in early stage NSCLC (non small cell lung cancer) at King’s Source: International Congress 2018 – Lung cancer: risk factors, supportive measures and quality improvement Year: 2018 Efficacy of a pulmonary rehabilitation programme (PRP) after lung resection (LR) for cancer Source: Annual Congress 2005 - Pulmonary rehabilitation: an evidence-based intervention Year: 2005 Surgical multimodality treatment for stage III non-small cell lung cancer (NSCLC) Source: Annual Congress 2006 - Integrative approaches for stage III non-small cell lung cancer Year: 2006 Customising chemotherapy in advanced nonsmall cell lung cancer: daily practice and perspectives Source: Eur Respir Rev 2011; 20: 45-52 Year: 2011 The influence of secondary infectious process on non-small cell lung cancer (NSCLC) patients survival Source: Eur Respir J 2007; 30: Suppl. 51, 280s Year: 2007 KRAS mutations in non-small cell lung cancer (NSCLC) – Experiences by routine molecular testing in a German lung cancer centre Source: Annual Congress 2011 - Epidemiology of lung cancer and screening Year: 2011 A new TNM classification is better than ISS at predicting survival in stage III unresectable non-small cell lung cancer (NSCLC). A study by the European lung cancer working party (ELCWP) Source: Eur Respir J 2003; 22: Suppl. 45, 163s Year: 2003